Science|Business Database: Coronavirus Funding Opportunities

This call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity.

Any aspect of coronavirus research. Applicants may request up to 300,000 francs for projects lasting up to 24 months. Bigger grants are conceivable, provided the applicant has good reasons for requesting a higher amount.

A call for R&D projects that can quickly contribute to improving the response of health systems to the impact of COVID-19, contributing to better patient management and the implementation of public health measures.

Part of the third phase of the PIPE programme, aimed at Innovative Research for SMEs. Its objective is to support research for SMEs which have conducted innovative research in the past.

Cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social beha

A rapid call to Austria businesses for COVID-19 projects lasting no longer than 12 months. To accelerate decision making, this call has a deadline of 8 April; a second call will have a deadline of 11 May.

A rapid response mechanism to fund research that will provide evidence for the Irish national and global efforts to deal with the virus outbreak.

Three separate calls to support networking, top up existing grantholders, and support projects already selected for funding.

The call will specifically give support to clinical and translational proposals that include clearly targeted technologies or projects to prevent, treat, monitor, or diagnose the COVID-19 disease.

Funding for public and private research into COVID-19 in the areas of epidemiological studies, diagnostics, therapeutics, behavioural science, mental health, and the development of medical and ICT devices.

A call for novel therapies, broad-spectrum antivirals, next-generation vaccines that may target new corona strains, multiple corona viruses or more than one type of virus, and strategies for first responders and emergency medical personnel.

Proposals should address COVID-19 infection in malignant and benign haematologic disorders or haematological and immunological manifestations in COVID-19 infection.

A rapid call to Austria businesses for COVID-19 projects lasting no longer than 12 months. The second part of the rapid call (the first part has a deadline of 8 April).

Grants for ongoing epidemiological, clinical, cell biology, genetic, or treatment studies in children.

A £10 million fund to support research to accelerate the development and testing of therapeutics that can be rapidly deployed to treat the symptoms of COVID-19.

Proposals sought for a clinical trial that accelerates the implementation of treatments for severe acute respiratory distress in patients infected with COVID-19 in order to support the response to the COVID-19 outbreak in Australia.

Funding for clinical trials to evaluate new drugs, devices, clinical guidance, approaches and technologies aimed at stopping the spread of COVID-19. Projects may range from proof-of-concept to large-scale trials.

This funding opportunity will be a complementary financial support for researchers financed by grants from Tematico program, Centres of Research, Innovation and Diffusion (CEPID), Engineering Research Centres (CPEs) and Young researchers

Applications must address clinical (hospital or outpatient) or community-related aspects of COVID-19. Translational projects will be preferred. Basic research at the cellular level, or into animals, will not be considered.

Projects lasting up to 9 months should collect data on the clinical course and outcome of COVID-19 in vulnerable populations, investigate long-term consequences of COVID-19 in patients, or test the safety and effectiveness of remdesivir in treatin